Study on the Clinical Application Value of Hydration Therapy Based on the Collapse Rate of Inferior Vena Cava to Prevent Contrast Nephropathy after Interventional Surgery

Abstract

Abstract: Objective To study the clinical application value of hydration therapy based on the collapse rate of Inferior vena cava to prevent contrast nephropathy after interventional surgery. Methods A total of 460 patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI) in our hospital from November 2021 to November 2023 were selected and divided into control group (n=232) and observation group (n=228) according to random number table method. The control group received hydration therapy guided by traditional methods. The observation group was guided by the measurement of inferior vena cava collapse rate (CI-IVC). The serum creatinine (SCr), endogenous creatinine clearance (eGFR), serum homocysteine (CysC), urea nitrogen (BUN), hypersensitive C-reactive protein (hs-CRP) and serum N-terminal B-type natriuretic peptide precursor (NT-proBNP) of the two groups were compared before and after surgery. Total contrast agent, total hydration; Left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD). Contrast agent nephropathy. Results Before surgery, there was no statistically significant difference in the levels of SCr, eGFR, CysC, BUN, hs CRP, and NT proBNP between the two groups of patients (P>0.05). There was no statistically significant difference in LVEF and LVEDD between the two groups of patients (P>0.05). After surgery, the SCr, eGFR, CysC, BUN, hs CRP, NT proBNP water levels in the observation group were significantly higher than those in the control group (P<0.05). There was no statistically significant difference in the total amount of contrast agent between the two groups of patients (P>0.05). The total amount of hydration in the observation group was significantly higher than that in the control group, with statistical significance (P<0.05). The incidence of contrast-enhanced nephropathy in the observation group was significantly reduced compared to the control group, with a significant difference (P<0.05). Conclusion Guiding patients to do hydration therapy by measuring the collapse rate of inferior vena cava can effectively reduce the incidence of contrast agent nephropathy, which is of high application value and worth popularizing.

Key words: collapse rate of inferior vena cava, hydration therapy, contrast agent nephropathy

CLC Number:

R445.1

YIN Fang, HOU Xing-zhi, SONG Zhi-ping. Study on the Clinical Application Value of Hydration Therapy Based on the Collapse Rate of Inferior Vena Cava to Prevent Contrast Nephropathy after Interventional Surgery[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(6): 155-158.

References

[1] 中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告 2019 概要[J].中国循环杂志,2020,35(9):833-854.
[2] 中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016)[J].中华心血管病杂志,2016,44(5):382-400.
[3] QIAN G, FU Z, GUO J, et al.Prevention of Contrast-Induced Nephropathy by Central Venous Pressure-Guided Fluid Administration in Chronic Kidney Disease and Congestive Heart Failure Patients[J]. JACC Cardiovasc Interv,2016,9(1):89-96.
[4] MCCULLOUGH P A, CHOI J P, FEGHALI G A, et al.Contrast-Induced Acute Kidney Injury[J]. J Am Coll Cardiol,2016,68(13):1465-1473.
[5] AZZALINI L, KALRA S.Contrast-Induced Acute Kidney Injury-Definitions, Epidemiology, and Implications[J].Interv Cardiol Clin,2020,9(3):299-309.
[6] FäHLING M, SEELIGER E, PATZAK A, et al. Understanding and preventing contrast-induced acute kidney injury[J]. Nat Rev Nephrol,2017,13(3):169-180.
[7] 金宏娟,刘哓燕,黄英.下腔静脉塌陷指数在指导早产儿肺出血液体治疗中的应用价值[J].中国临床新医学,2022,15(6):528-532.
[8] WANG J, AI X, LI L, et al.Alprostadil protects type 2 diabetes mellitus patients treated with metformin from contrast-induced nephropathy[J]. Int Urol Nephrol,2017,49(11):2019-2026.
[9] BRAR S S, AHARONIAN V, MANSUKHANI P, et al.Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial[J].Lancet,2014,383(9931):1814-1823.
[10] 袁玲霞. 碘普罗胺联合水化治疗在预防糖尿病患者PCI术后对比剂肾病中的应用价值[J].罕少疾病杂志,2020,27(2):47-48,98.
[11] STAWICKI S P, KENT A, PATIL P, et al.Dynamic behavior of venous collapsibility and central venous pressure during standardized crystalloid bolus: A prospective, observational, pilot study[J]. Int J Crit Illn Inj Sci,2015,5(2):80-84.
[12] 林凯玲. 短期强化饮水联合水化在预防冠脉介入术后造影剂肾损伤中的应用和护理价值分析[J].心血管病防治知识(下半月), 2020,10(33):80-82.
[13] 杨永强,吴婷玉,黄楷森,等.充分水化联合尼可地尔对于心肾功能不全患者造影剂肾病预防作用的临床分析[J].心脑血管病防治,2022,22(3):73-75.
[14] 胡乃峰. 左卡尼汀联合水化对肾功能不全患者造影剂肾病的预防[J].中国循证心血管医学杂志,2021,13(7):873-875.
[15] 季建琴,陈红.精细化口服水化干预对冠状动脉介入治疗并发造影剂肾病的预防作用[J].中国基层医药,2020,27(4):501-504.
[16] 余雅真. 改良水化疗法对预防支架植入术后造影剂肾病的作用[J].中国卫生标准管理,2020,11(20):108-111.
[17] NIJSSEN E C, RENNENBERG R J, NELEMANS P J, et al.Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial[J]. Lancet,2017,389(10076):1312-1322.
[18] 马光,王国良,侯德和,等.别嘌呤醇联合水化对冠状动脉介入术后造影剂肾病预防作用的Meta分析[J].中国循证心血管医学杂志,2020,12(7):788-793.
[19] 徐秋妹,张燕,陈海林.下腔静脉塌陷指数在老年髋部骨折患者行PFNA术中容量治疗的应用分析[J].首都食品与医药,2022,29(6):33-35.
[20] BEI W J, WANG K, LI H L, et al.Safe Hydration to Prevent Contrast-Induced Acute Kidney Injury and Worsening Heart Failure in Patients with Renal Insufficiency and Heart Failure Undergoing Coronary Angiography or Percutaneous Coronary Intervention[J]. Int Heart J,2019,60(2):247-254.